Çocukluk Çağında Kardiyovasküler Risk Bakımından Eski ve Yeni Lipit Biyobelirteçler

McNamara K, Alzubaidi H, Jackson J.K. Cardiovascular disease as a leading cause of death: How are pharmacists getting involved? Integr. Pharm. Res. Pract. ; 2019; 8, 1–11. doi: 10.2147/IPRP.S133088.

Linton M.F, Yancey P.G, Davies S.S, et al. The Role of Lipids and Lipoproteins in Atherosclerosis. In Comprehensive Endocrinology Book; Endotext, Feingold, K.R., Anawalt, B., Eds.; MDText.com, Inc. : South Dartmouth, MA, USA; 2019; PMID: 26844337

Mayerl, C, Lukasser, M, Sedivy, R, et al. Atherosclerosis research from past to present—On the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. Virchows Arch. ; 2006; 449, 96–103. doi: 10.1007/s00428-006-0176-7

Minelli S, Minelli P, Montinari MR. Reflections on Atherosclerosis: Lesson from the Past and Future Research Directions. J Multidiscip Healthc. ; 2020; 17;13:621-633. doi: 10.2147/JMDH.S254016.

Ross R, Atherosclerosis—An Inflammatory Disease. New England Journal of Medicine; 1999; 340, 115–126. doi: 10.1056/NEJM199901143400207

Li L, Liu S, Tan J, et al. Recent Advance in Treatment of Atherosclerosis: Key Targets and Plaque-Positioned Delivery Strategies. J. Tissue Eng. ; 2022; 13, doi: 10.1177/20417314221088508

Pirillo A, Bonacina F, Norata GD, et al. The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. Curr Atheroscler Rep. ; 2018; 14;20(3):12. doi: 10.1007/s11883-018-0715-0.

McGill HC Jr, McMahan CA, Herderick EE, et al. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr. ; 2000; 72(5 Suppl):1307S-1315S. doi: 10.1093/ajcn/72.5.1307s.

Milei J, Ottaviani G, Lavezzi AM, et al. Perinatal and infant early atherosclerotic coronary lesions. Can J Cardiol. ; 2008; 24(2):137-41. doi:10.1016/s0828-282x(08)70570-1.

Bridger T, Childhood obesity and cardiovascular disease, Paediatrics & Child Health, Volume 14, Issue 3, 09; Pages 177–182, https://doi.org/10.1093/pch/14.3.177

Raghuveer G. Lifetime cardiovascular risk of childhood obesity. Am J Clin Nutr. ; 2010; 91(5):1514S-1519S. doi: 10.3945/ajcn.2010.28701D.

Li-Beisson Y, Nakamura Y, Harwood J. Lipids: From Chemical Structures, Biosynthesis, and Analyses to Industrial Applications. Subcell Biochem. ; 2016; 86:1-18. doi: 10.1007/978-3-319-25979-6_1.

Hinterwirth H, Stegemann C, Mayr M. Lipidomics: quest for molecular lipid biomarkers in cardiovascular disease. Circ Cardiovasc Genet. ; 2014; 7(6): 941-54. doi: 10.1161/CIRCGENETICS.114.000550.

Močnik M, Marčun Varda N. Lipid Biomarkers and Atherosclerosis-Old and New in Cardiovascular Risk in Childhood. Int J Mol Sci. ; 2023; 24(3):2237. doi: 10.3390/ijms24032237.

Feingold, K.R. Introduction to Lipids and Lipoproteins. In Comprehensive Endocrinology Book; Endotext, Feingold, K.R., Anawalt, B., Eds.; MDText.com, Inc. : South Dartmouth, MA,USA; 2021; PMID: 26247089.

Berenson GS, Srnivasan SR; Bogalusa Heart Study Group. Cardiovascular risk factors in youth with implications for aging: the Bogalusa Heart Study. Neurobiol Aging. ; 2005; 26(3):303-7. doi: 10.1016/j.neurobiolaging.2004.05.009.

Steinberger J, Daniels SR; American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young); American Heart Association Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation.;2003;18;107(10):1448-53.doi: 10.1161/01.cir.0000060923.07573.f2.

Gröber-Grätz D, Widhalm K, de Zwaan M, et al.. Body mass index or waist circumference: which is the better predictor for hypertension and dyslipidemia in overweight/obese children and adolescents? Association of cardiovascular risk related to body mass index or waist circumference. Horm Res Paediatr. ; 2013; 80(3):170-8. doi: 10.1159/000354224.

Korsten-Reck U, Kromeyer-Hauschild K, Korsten K, et al. Frequency of secondary dyslipidemia in obese children. Vasc Health Risk Manag. ; 2008; 4(5):1089-94. doi: 10.2147/vhrm.s2928.

Kavey RE. Combined dyslipidemia in childhood. J Clin Lipidol. ; 2015; Sep-;9(5 Suppl):S41-56. doi: 10.1016/j.jacl.2015.06.008.

Strong JP, Malcom GT, Newman WP 3rd, et al. Early lesions of atherosclerosis in childhood and youth: natural history and risk factors. J Am Coll Nutr.;1992;11 Suppl:51S-54S. doi: 10.1080/07315724.1992.10737984.

Guardamagna O, Abello F, Saracco P, et al. Endothelial activation, inflammation and premature atherosclerosis in children with familial dyslipidemia. Atherosclerosis. ; 2009; 207(2):471-5. doi: 10.1016/j.atherosclerosis.2009.06.006.

Morrison KM, Dyal L, Conner W, et al. Cardiovascular risk factors and non-invasive assessment of subclinical atherosclerosis in youth. Atherosclerosis. ; 2010; 208(2):501-5. doi: 10.1016/j.atherosclerosis.2009.07.034.

Litwin SE. Childhood obesity and adulthood cardiovascular disease: quantifying the lifetime cumulative burden of cardiovascular risk factors. J Am Coll Cardiol. ; 2014; 14;64(15):1588-90. doi: 10.1016/j.jacc.2014.07.962.

Magnussen CG, Venn A, Thomson R, et al. The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Determinants of Adult Health) study. J Am Coll Cardiol. ; 2009; 10;53(10):860-9. doi: 10.1016/j.jacc.2008.09.061.

Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA. ; 2003; 290(17):2271-6. doi: 10.1001/jama.290.17.2271.

Srinivasan SR, Frontini MG, Xu J, et al. Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study. Pediatrics. ; 2006; 118(1):201-6. doi: 10.1542/peds.2005-1856.

Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med.;. ; 2011; 17;365(20):1876-85. doi: 10.1056/NEJMoa1010112.

Andersen LB, Harro M, Sardinha LB, et al. Physical activity and clustered cardiovascular risk in children: a cross-sectional study (The European Youth Heart Study). Lancet. ; 2006; 22;368(9532):299-304. doi: 10.1016/S0140-6736(06)69075-2.

Cesa CC, Sbruzzi G, Ribeiro RA, et al. Physical activity and cardiovascular risk factors in children: meta-analysis of randomized clinical trials. Prev Med. ; 2014; 69:54-62. doi: 10.1016/j.ypmed.2014.08.014.

Manfroi WC, Zago AJ, Campos M, et al. Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease? Arq Bras Cardiol. ; 1999; 72(6):657-68. English, Portuguese. doi: 10.1590/s0066-782x1999000600001.

Welsh C, Celis-Morales CA, Brown R, et al. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation. ; 2019; 13;140(7):542-552. doi: 10.1161/CIRCULATIONAHA.119.041149.

Anastasiou G, Sakka E, Blathra E, et al. Lipoprotein(a): A Concealed Precursor of Increased Cardiovascular Risk? A Real-World Regional Lipid Clinic Experience. Arch Med Res. ; 2021; 52(4):397-404. doi: 10.1016/j.arcmed.2020.12.003.

Gulayin PE, Lozada A, Schreier L, et al. Elevated Lipoprotein(a) prevalence and association with family history of premature cardiovascular disease in general population with moderate cardiovascular risk and increased LDL cholesterol. Int J Cardiol Heart Vasc. ; 2022; 31;42:101100. doi: 10.1016/j.ijcha.2022.101100.

Guardamagna O, Abello F, Anfossi G, et al. Lipoprotein(a) and family history of cardiovascular disease in children with familial dyslipidemias. J Pediatr. ; 2011; 159(2):314-9. doi: 10.1016/j.jpeds.2011.01.038.

Sultan SM, Schupf N, Dowling MM, et al. Review of lipid and lipoprotein(a) abnormalities in childhood arterial ischemic stroke. Int J Stroke. ; 2014; 9(1):79-87. doi: 10.1111/ijs.12136.

Tounian P, Aggoun Y, Dubern B, et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet. ; 2001; 27;358(9291):1400-4. doi: 10.1016/S0140-6736(01)06525-4.

Barroso WKS, Souza ALL. Obesity, Overweight, Body Adiposity and Cardiovascular Risk in Children and Adolescents. Arq Bras Cardiol. ; 2020; 28;115(2):172-173. English, Portuguese. doi: 10.36660/abc.20200540.

Savas Erdeve S, Simsek E, Dallar Y, et al. Utility of ApoB/ApoA1 ratio for the prediction of cardiovascular risk in children with metabolic syndrome. Indian J Pediatr. ; 2010; 77(11):1261-5. doi: 10.1007/s12098-010-0217-8.

Koivistoinen T, Hutri-Kähönen N, Juonala M, et al. Apolipoprotein B is related to arterial pulse wave velocity in young adults: the Cardiovascular Risk in Young Finns Study. Atherosclerosis. ; 2011; 214(1):220-4. doi: 10.1016/j.atherosclerosis.2010.10.037.

Czeck MA, Northrop EF, Evanoff NG, et al. Relationship of Apolipoproteins with Subclinical Cardiovascular Risk in Youth. J Pediatr. ; 2020; 227:199-203.e1. doi: 10.1016/j.jpeds.2020.08.017.

Chen WL, Tain YL, Chen HE, et al. Cardiovascular Disease Risk in Children With Chronic Kidney Disease: Impact of Apolipoprotein C-II and Apolipoprotein C-III. Front Pediatr. ; 2021; 9:706323. doi: 10.3389/fped.2021.706323.

Marais AD. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology. ; 2019; 51(2):165-176. doi: 10.1016/j.pathol.2018.11.002.

Taylor AE, Guthrie PA, Smith GD, Golding J, Sattar N, Hingorani AD, Deanfield JE, Day IN. IQ, educational attainment, memory and plasma lipids: associations with apolipoprotein E genotype in 5995 children. Biol Psychiatry. ; 2011; 70(2):152-8. doi: 10.1016/j.biopsych.2010.10.033.

Tsimikas S. Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr Atheroscler Rep. ; 2006; 8(1):55-61. doi: 10.1007/s11883-006-0065-1.

Tsimikas S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am J Cardiol. ; 2006; 98(11A):9P-17P. doi: 10.1016/j.amjcard.2006.09.015.

Fraley AE, Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol. ; 2006; 17(5):502-9. doi: 10.1097/01.mol.0000245255.40634.b5.

Tian K, Ogura S, Little PJ, et al. Targeting LOX-1 in atherosclerosis and vasculopathy: current knowledge and future perspectives. Ann N Y Acad Sci. ; 2019; 1443(1):34-53. doi: 10.1111/nyas.13984.

Varghese DS, Ali BR. Pathological Crosstalk Between Oxidized LDL and ER Stress in Human Diseases: A Comprehensive Review. Front Cell Dev Biol. ; 2021; 9:674103. doi: 10.3389/fcell.2021.674103.

Zingg JM, Vlad A, Ricciarelli R. Oxidized LDLs as Signaling Molecules. Antioxidants (Basel). ; 2021; 10(8):1184. doi: 10.3390/antiox10081184.

Trpkovic A, Resanovic I, Stanimirovic J, et al. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci. ; 2015; 52(2):70-85. doi: 10.3109/10408363.2014.992063.

Norris AL, Steinberger J, Steffen LM, et al. Circulating oxidized LDL and inflammation in extreme pediatric obesity. Obesity (Silver Spring). ; 2011; 19(7):1415-9. doi: 10.1038/oby.2011.21.

Kelly AS, Jacobs DR Jr, Sinaiko AR, et al. Relation of circulating oxidized LDL to obesity and insulin resistance in children. Pediatr Diabetes. ; 2010; 11(8):552-5. doi: 10.1111/j.1399-5448.2009.00640.x.

Järvisalo MJ, Lehtimäki T, Raitakari OT. Determinants of arterial nitrate-mediated dilatation in children: role of oxidized low-density lipoprotein, endothelial function, and carotid intima-media thickness. Circulation. ; 2004; 109(23):2885-9. doi: 10.1161/01.CIR.0000129304.98566.D8.

Nascimento H, Alves AI, Coimbra S, et al. Bilirubin is independently associated with oxidized LDL levels in young obese patients. Diabetol Metab Syndr. ; 2015; 7:4. doi: 10.1186/1758-5996-7-4.

Marin MT, Dasari PS, Tryggestad JB, et al. Oxidized HDL and LDL in adolescents with type 2 diabetes compared to normal weight and obese peers. J Diabetes Complications. ; 2015; 29(5):679-85. doi: 10.1016/j.jdiacomp.2015.03.015.

Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. ; 2007; 27(8):1788-95. doi: 10.1161/ATVBAHA.107.145805.

Colantuono R, Pavanello C, Pietrobattista A, et al. Case report: Unusual and extremely severe lipoprotein X-mediated hypercholesterolemia in extrahepatic pediatric cholestasis. Front Pediatr. 2022;10:969081. doi: 10.3389/fped.2022.969081.

Amar MJA, Freeman LA, Nishida T, et al. LCAT protects against Lipoprotein-X formation in a murine model of drug-induced intrahepatic cholestasis. Pharmacol Res Perspect. ; 2019; 8(1):e00554. doi: 10.1002/prp2.554.

Dimitroglou Y, Sakalidis A, Mavroudis A, et al. Lipoprotein-associated Phospholipase A2 in Coronary Artery Disease. Curr Top Med Chem. ; 2022; 22(28):2344-2354. doi: 10.2174/1568026623666221027145545.

Colley KJ, Wolfert RL, Cobble ME. Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J. ; 2011; 2(1):27-38. doi: 10.1007/s13167-011-0063-4.

Alkuraishy HM, Al-Gareeb AI, Waheed HJ. Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins. J Neurosci Rural Pract. ; 2018; -;9(4):496-503. doi: 10.4103/jnrp.jnrp_97_18.

Öngen B, Kalkan Uçar S, Levent E, et al. Lipoprotein-associated phospholipase A2: a new marker to determine cardiovascular risk in hypercholesterolemic dyslipidaemic children. Ann Clin Biochem. ; 2017; Sep;54(5):539-547. doi: 10.1177/0004563216671338.

Ferraro F, Martín M, Verona J, et al. Increased Cholesteryl Ester Transfer Protein and Lipoprotein-Associated Phospholipase A2 Activities in Children and Adolescents Presenting High Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio. Indian J Pediatr. ; 2021; 88(12):1180-1186. doi: 10.1007/s12098-021-03806-5.

Sakka S, Siahanidou T, Voyatzis C, et al. Elevated circulating levels of lipoprotein-associated phospholipase A2 in obese children. Clin Chem Lab Med. ; 2015; 53(7):1119-25. doi: 10.1515/cclm-2014-1081.

da Silva IT, Timm Ade S, Damasceno NR. Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study. Lipids Health Dis. ; 2013; 12:19. doi: 10.1186/1476-511X-12-19.

Alexandropoulou I, Lantzanaki-Syrpou M, Grammatikopoulou M.G, et al. Ceramides as Dietary Biomarkers. In Biomarkers in Nutrition. Biomarkers in Disease: Methods, Discoveries and Applications; Patel, V.B., Preedy, V.R., Eds. ; Springer: Cham, Switzerland; 2022; pp. 1–15.

Summers SA, Chaurasia B, Holland WL. Metabolic Messengers: ceramides. Nat Metab. ; 2019; 1(11):1051-1058. doi: 10.1038/s42255-019-0134-8.

Laaksonen R, Ekroos K, Sysi-Aho M, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. ; 2016; 37(25):1967-76. doi: 10.1093/eurheartj/ehw148.

70. Meeusen J.W, Donato L.J, Bryant S.C, et al. Jaffe, A.S. Plasma Ceramides. Arterioscler. Thromb. Vasc. Biol. ; 2018; 38, 1933–1939.

Wasilewska N, Bobrus-Chociej A, Harasim-Symbor E, et al. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease. Lipids Health Dis. ; 2018; Sep 12;17(1):216. doi: 10.1186/s12944-018-0855-9.

Sands MS. Farber disease: understanding a fatal childhood disorder and dissecting ceramide biology. EMBO Mol Med. ; 2013; 5(6):799-801. doi: 10.1002/emmm.201302781.

Lee CK, Liao CW, Meng SW, et al. Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis. Biomedicines. ; 2021; 9(8):985. doi: 10.3390/biomedicines9080985.

Ference BA, Kastelein JJP, Ray KK, et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. ; 2019; 321(4):364-373. doi: 10.1001/jama.2018.20045.

Hegele RA, Ginsberg HN, Chapman MJ, et al. European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. ; 2014; 2(8):655-66. doi: 10.1016/S2213-8587(13)70191-8.

Mahdy Ali K, Wonnerth A, Huber K, et al. Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities. Br J Pharmacol. ; 2012; 167(6):1177-94. doi: 10.1111/j.1476-5381.2012.02081.x.

Brea A, Hernández-Mijares A, Millán J, et al. Non-HDL cholesterol as a therapeutic goal. Clin Investig Arterioscler. ; 2019; 31 Suppl 2:28-33. English, Spanish. doi: 10.1016/j.arteri.2019.07.002.

Rana JS, Boekholdt SM, Kastelein JJ, et al. The role of non-HDL cholesterol in risk stratification for coronary artery disease. Curr Atheroscler Rep. ; 2012; 14(2):130-4. doi: 10.1007/s11883-011-0224-x.

Brunner FJ, Waldeyer C, Ojeda F, et al. Multinational Cardiovascular Risk Consortium. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet. ; 2019; 394(10215):2173-2183. doi: 10.1016/S0140-6736(19)32519-X.

Wang G, Jing J, Wang A, et al. China National Stroke Registry II Investigators. Non-High-Density Lipoprotein Cholesterol Predicts Adverse Outcomes in Acute Ischemic Stroke. Stroke. ; 2021; 52(6):2035-2042. doi: 10.1161/STROKEAHA.120.030783.

Wen J, Huang Y, Lu Y, et al. Associations of non-high-density lipoprotein cholesterol, triglycerides and the total cholesterol/HDL-c ratio with arterial stiffness independent of low-density lipoprotein cholesterol in a Chinese population. Hypertens Res. ; 2019; 42(8):1223-1230. doi: 10.1038/s41440-019-0251-5.

Tanaka F, Makita S, Onoda T, et al. Iwate-Kenco Study Group. Predictive value of lipoprotein indices for residual risk of acute myocardial infarction and sudden death in men with low-density lipoprotein cholesterol levels <120 mg/dl. Am J Cardiol. ; 2013; 112(8):1063-8. doi: 10.1016/j.amjcard.2013.05.049.

Carr SS, Hooper AJ, Sullivan DR, et al. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. ; 2019; 51(2):148-154. doi: 10.1016/j.pathol.2018.11.006.

Mach F, Baigent C, Catapano A.L, et al. ; 2019; ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 2020, 41, 111–188 doi.org/10.1093/eurheartj/ehr158

Pencina KM, Thanassoulis G, Wilkins JT, et al. Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention. J Am Coll Cardiol. ; 2019; 74(1):70-79. doi: 10.1016/j.jacc.2019.04.047.

Armstrong MK, Fraser BJ, Hartiala O, et al. Association of Non-High-Density Lipoprotein Cholesterol Measured in Adolescence, Young Adulthood, and Mid-Adulthood With Coronary Artery Calcification Measured in Mid-Adulthood. JAMA Cardiol. ; 2021; 6(6):661-668. doi: 10.1001/jamacardio.2020.7238.

Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation. ; 1983; 67(4):730-4. doi:10.1161/01.cir.67.4.730.

Liu H, Deng X, Peng Y, et al. Meta-analysis of serum non-high-density lipoprotein cholesterol and risk of coronary heart disease in the general population. Clin Chim Acta. ; 2017; 471:23-28. doi: 10.1016/j.cca.2017.05.006.

Millán J, Pintó X, Muñoz A, et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. ; 2009; 5:757-65. Epub 2009 Sep 18. PMID: 19774217; PMCID: PMC2747394.

Bhardwaj S, Bhattacharjee J, Bhatnagar M.K, et al. Atherogenic Index of Plasma, Castelli Risk Index and Atherogenic Coefficient-New Parameters in Assessing Cardiovascular Risk. Int. J. Pharm. Biol. Sci. ; 2013; 3, 359–364.

Ray S, Saikia D, Vashisht Y, Sharma S, Meena RK, Kumar M. Dyslipidemia and atherogenic indexes in children with transfusion-dependent thalassemia. Hematol Transfus Cell Ther. ; 2024; -;46(4):345-351. doi: 10.1016/j.htct.2023.02.006.

Andrades CDS, Poletti VV, Closs VE, Gustavo ADS, Oliveira MDS, Donadio MVF, Feoli AMP. Prevalence of dyslipidemia, atherogenic and cardiovascular risk in overweight and obese adolescents. Rev Paul Pediatr. ; 2023; 41:e2021312. doi: 10.1590/1984-0462/2023/41/2021312.

Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag. ; 2016; 12:171-83. doi: 10.2147/VHRM.S104369.

Castañer O, Pintó X, Subirana I, et al. Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease. J Am Coll Cardiol. ; 2020; 76(23):2712-2724. doi: 10.1016/j.jacc.2020.10.008.

Miller M, Stone NJ, Ballantyne C, et al. American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. ; 2011; 123(20):2292-333. doi: 10.1161/CIR.0b013e3182160726.

Su X, Kong Y, Peng D. Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. Lipids Health Dis. ; 2019; 18(1):134. doi: 10.1186/s12944-019-1080-x.

Torres-Costoso A, Martínez-Vizcaíno V, Oliveira A, et al. Beyond LDL cholesterol: remnant cholesterol is associated with cardiometabolic risk factors in children. BMC Med. ; 2025; 23(1):28. doi: 10.1186/s12916-025-03859-9.

Li YW, Kao TW, Chang PK, et al. Atherogenic index of plasma as predictors for metabolic syndrome, hypertension and diabetes mellitus in Taiwan citizens: a 9-year longitudinal study. Sci Rep. ; 2021; 11(1):9900. doi: 10.1038/s41598-021-89307-z.

Khakurel G, Kayastha R, Chalise S, et al. Atherogenic Index of Plasma in Postmenopausal Women. J Nepal Health Res Counc. ; 2018; 16(2):175-177. PMID: 29983433.

Nogay NH Evaluation of the correlation between plasma atherogenic index and cardiometabolic risk factors in children and adolescents: Could it be superior to the TG/HDL-C ratio? J Pediatr Endocrinol Metab. ; 2017; 30(9):947–955. doi: 10.1515/jpem-2016-0479.

Mangalesh S, Yadav P, Dudani S, et al. Atherogenic index of plasma predicts coronary artery disease severity and major adverse cardiac events in absence of conventional risk factors. Coron Artery Dis. ; 2022; 33(7):523-530. doi: 10.1097/MCA.0000000000001166.

102. Shui X, Chen Z, Wen Z, et al. Association of Atherogenic Index of Plasma With Angiographic Progression in Patients With Suspected Coronary Artery Disease. Angiology. ; 2022; 73(10):927-935. doi: 10.1177/00033197221080911.